These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19786020)

  • 1. Huntington's disease: silencing a brutal killer.
    Pfister EL; Zamore PD
    Exp Neurol; 2009 Dec; 220(2):226-9. PubMed ID: 19786020
    [No Abstract]   [Full Text] [Related]  

  • 2. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
    Pfister EL; Kennington L; Straubhaar J; Wagh S; Liu W; DiFiglia M; Landwehrmeyer B; Vonsattel JP; Zamore PD; Aronin N
    Curr Biol; 2009 May; 19(9):774-8. PubMed ID: 19361997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gene silencing approaches for the treatment of Huntington's disease].
    Merienne N; Déglon N
    Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained effects of nonallele-specific Huntingtin silencing.
    Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
    Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.
    Hu J; Liu J; Corey DR
    Chem Biol; 2010 Nov; 17(11):1183-8. PubMed ID: 21095568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
    van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
    Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
    Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
    Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.
    Hu J; Matsui M; Corey DR
    Ann N Y Acad Sci; 2009 Sep; 1175():24-31. PubMed ID: 19796074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haplotype background, repeat length evolution, and Huntington's disease.
    Falush D
    Am J Hum Genet; 2009 Dec; 85(6):939-42. PubMed ID: 20004772
    [No Abstract]   [Full Text] [Related]  

  • 10. Progress and challenges in RNA interference therapy for Huntington disease.
    Harper SQ
    Arch Neurol; 2009 Aug; 66(8):933-8. PubMed ID: 19667213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Huntington's disease. Expanding horizons for treatment.
    McMurray CT
    Lancet; 2001 Dec; 358 Suppl():S37. PubMed ID: 11784586
    [No Abstract]   [Full Text] [Related]  

  • 12. Delivering a disease-modifying treatment for Huntington's disease.
    Godinho BM; Malhotra M; O'Driscoll CM; Cryan JF
    Drug Discov Today; 2015 Jan; 20(1):50-64. PubMed ID: 25256777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
    Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
    Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.
    Fiszer A; Olejniczak M; Switonski PM; Wroblewska JP; Wisniewska-Kruk J; Mykowska A; Krzyzosiak WJ
    BMC Mol Biol; 2012 Mar; 13():6. PubMed ID: 22397573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.
    Conroy F; Miller R; Alterman JF; Hassler MR; Echeverria D; Godinho BMDC; Knox EG; Sapp E; Sousa J; Yamada K; Mahmood F; Boudi A; Kegel-Gleason K; DiFiglia M; Aronin N; Khvorova A; Pfister EL
    Nat Commun; 2022 Oct; 13(1):5802. PubMed ID: 36192390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.
    Jimenez-Sanchez M; Licitra F; Underwood BR; Rubinsztein DC
    Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 27940602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurobiology of Huntington's disease.
    Sharp AH; Ross CA
    Neurobiol Dis; 1996 Feb; 3(1):3-15. PubMed ID: 9173909
    [No Abstract]   [Full Text] [Related]  

  • 18. The enigma of Huntington's disease.
    Cattaneo E; Rigamonti D; Zuccato C
    Sci Am; 2002 Dec; 287(6):92-7. PubMed ID: 12469651
    [No Abstract]   [Full Text] [Related]  

  • 19. Huntington's disease. In reverse gear.
    Bates G
    Nature; 2000 Apr; 404(6781):944-5. PubMed ID: 10801109
    [No Abstract]   [Full Text] [Related]  

  • 20. Lentiviral-mediated gene transfer of siRNAs for the treatment of Huntington's disease.
    Cambon K; Déglon N
    Methods Mol Biol; 2013; 1010():95-109. PubMed ID: 23754221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.